[contact-form-7 id=”17″ title=”Contact form 1″]
- CNA Transitions to AIR Worldwide as its Primary Catastrophe Risk Management Platform
- Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe
- Trip.com Group releases “2020 Dragon Boat Festival Holiday Big Data Report”
- Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in China
- Junshi Biosciences Announces Approval of “B” Marker Removal from Company’s Stock Name by HKEX